Om du vill rapportera en biverkning gällande en av Lillys produkter, kontakta oss via e-post på DK_PHv@lilly.com eller på telefon +45 4526 6040. Har du ytterligare medicinska frågor gällande en av Lillys produkter, kontakta oss via länken ovan.
Baqsimi ® (glukagon näspulver)
Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska
Absorption
Glucagon absorption via the nasal route achieved mean peak plasma levels of 6130 pg/mL at 15 minutes.1
Bioavailability
In an insulin-induced hypoglycemia study in adults with T1DM, the mean total plasma glucagon exposure after 3 mg NG was approximately 80% of that observed with 1 mg IM glucagon. This suggests that the relative bioavailability of NG is about 25% to 30% of IM glucagon.2
Distribution
The apparent volume of distribution of glucagon was approximately 885 L via the nasal route.1
Metabolism
Glucagon is known to be degraded in the liver, kidneys, and plasma.1
Elimination
The mean half-life of glucagon was approximately 38 minutes via the nasal route.1
Pediatrics
In paediatric patients (4 to < 17 years), glucagon absorption via the nasal route, achieved mean peak plasma levels between 15 and 20 minutes.1
The median half-life was 21 to 31 minutes via the intranasal route.2
Special Populations
No formal studies have been performed to evaluate renal or hepatic impairment.1
Common cold with nasal congestion with or without concomitant use of a decongestant did not impact pharmacokinetics via the nasal route.1
1. Baqsimi [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
2. Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Glossary
IM = intramuscular
NG = nasal glucagon (glucagon nasal powder)
PK = pharmacokinetic
T1DM = type 1 diabetes mellitus
Datum fӧr senaste ӧversyn 2019 M07 24